USANA Finalizes Compensation for New CEO Kevin Guest and Outgoing CEO Jim Brown
USNA is trading near its 52-week low of $18.48 (14% above the low).
Summary
USANA Health Sciences, Inc. filed an amendment to disclose the compensation arrangements for its new CEO, Kevin Guest, including a substantial performance-based equity award, and the severance package for former CEO Jim Brown.
Key Events · Executive and Board Changes · USNA
-
Former CEO Jim Brown's Transition Agreement
Jim Brown will serve as a strategic advisor until December 31, 2026, receiving an $825,000 base salary and a 2025 bonus. He will also receive a $1.5 million severance, paid in installments, and 18 months of COBRA coverage, contingent on a release of claims.
-
New CEO Kevin Guest's Compensation Package
Kevin Guest's annual base salary is set at $850,000, with a target bonus of 100% of his base salary. He will receive a $1.7 million restricted stock unit award for 2026.
-
Long-Term Performance Incentive for New CEO
Mr. Guest is eligible for a long-term performance incentive award, potentially worth up to $3.4 million, tied to the company's share price outperforming the Russell 2000 Index and achieving positive total shareholder return over a four-year period ending January 1, 2030.
Analysis · USNA · Life Sciences
This 8-K/A filing provides crucial financial details regarding the executive transition previously announced on January 8, 2026. The company has finalized a transition agreement with former CEO Jim Brown, outlining his strategic advisor role and a $1.5 million severance package. More significantly, the filing details the comprehensive compensation for new CEO Kevin Guest, which includes a base salary, target bonus, and a substantial restricted stock unit award. A key component is a long-term performance incentive award, potentially valued up to $3.4 million, designed to align Mr. Guest's compensation with the company's share price outperformance against the Russell 2000 Index and positive total shareholder return over a four-year period. This structure aims to incentivize long-term value creation and provides clarity on the financial implications of the leadership change.
At the time of this filing, USNA was trading at $21.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $386.5M. The 52-week trading range was $18.48 to $38.32. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.